Related Experiment Video
Updated: Aug 9, 2026

Biochemical Titration of Glycogen In vitro
Published on: November 24, 2013
The long-term outcome of patients with glycogen storage disease type Ia
1Department of Paediatrics, University Hospital of the University of Groningen, The Netherlands.
Insights
This study on pediatric patients found that frequent feeding regimens, including nocturnal gastric drip feeding, improved height standard deviation scores in 16 out of 20 patients. Liver adenomas and hypoglycemia were noted in some participants.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
- Gastroenterology
Background:
- Glycogen storage disease type I (GSD Ia) is a rare inherited metabolic disorder.
- Patients with GSD Ia often present with hypoglycemia, hepatomegaly, and growth failure.
- Long-term complications include liver adenomas and metabolic derangements.
Purpose of the Study:
- To retrospectively analyze clinical characteristics and outcomes in a cohort of GSD Ia patients.
- To evaluate the efficacy of intensive feeding regimens on growth and metabolic parameters.
- To assess the prevalence of complications such as liver adenomas and hyperlipidemia.
Main Methods:
- Retrospective analysis of 41 patients (age >10 years) from five European centers.
- Assessment of clinical data including height percentile, hypoglycemia, hepatomegaly, and biochemical markers.
- Prospective evaluation of 20 patients before and after at least 5 years of intensive feeding therapy (daytime feeds + nocturnal gastric drip).
Main Results:
- 19 patients were below the 3rd height percentile; 6 experienced hypoglycemia.
- Hepatomegaly was present in 39/40 patients; 11/27 had marked hepatomegaly.
- Liver adenomas detected in 11/39 patients; hypercholesterolemia and hypertriglyceridemia were common.
- Intensive feeding improved height standard deviation scores (SDS) in 16/20 patients (responders).
Conclusions:
- Intensive feeding regimens, including nocturnal gastric drip, significantly improve growth in GSD Ia patients.
- Despite treatment, hypoglycemia and hepatomegaly persist in a subset of patients.
- Regular monitoring for liver adenomas and metabolic complications remains crucial in GSD Ia management.
Abstract:
Forty-one patients (16 females and 25 males) over 10 years of age from five different European centres were studied retrospectively. Of those patients 19 were below the 3rd percentile for height. Hypoglycaemia was still reported in 6 patients. Hepatomegaly was present in 39 out of 40, while 11 out of 27 reported patients had marked hepatomegaly (> 10 cm below the costal margin in the midclavicular line). Adenomas were detected in 11 out of 39 patients, alpha-1-fetoprotein was reported to be within normal limits in a total of 22 patients of whom 6 had adenomas. Blood cholesterol concentration was elevated in 31 out of 38 patients, in 7 greater than 10.0 mmol/l. Blood triglycerides were elevated in 29 out of 34 patients, in 8 patients greater than 4.0 mmol/l. Blood uric acid concentration was elevated in 19 out of 35 patients, 12 of them being treated with allopurinol. Mental development was reported to be normal in 32 out of 37 patients. Since limited information on treatment was available no significant differences between treatment groups could be detected. In order to evaluate the effect of treatment, 20 patients (10 females and 10 males) of one centre were studied before and after at least 5 years of treatment. This treatment consisted of frequent feedings during the day together with nocturnal gastric drip feeding. Patients were divided into responders (n = 16) and non-responders (n = 4) depending on their (change in) SDS (standard deviation score) for height. Liver adenomas were detected in 3 patients, of which one was a non-responder. Alpha-fetoprotein was normal in all patients.(ABSTRACT TRUNCATED AT 250 WORDS)
More Related Videos
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Inborn Errors of Metabolism
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
Type II Diabetes II: Pathophysiology

